NasdaqGS - Nasdaq Real Time Price • USD
Mind Medicine (MindMed) Inc. (MNMD)
At close: April 26 at 4:00 PM EDT
After hours: April 26 at 7:36 PM EDT
Key Executives
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Robert Barrow | CEO & Director | 956.1k | -- | 1989 |
| Mr. Schond L. Greenway M.B.A. | Chief Financial Officer | 343.28k | -- | 1972 |
| Dr. Daniel Rollings Karlin M.A., M.D. | Chief Medical Officer | 663.63k | -- | 1980 |
| Dr. Miriam Halperin Wernli M.B.A., Ph.D. | Executive President | 552.46k | -- | 1953 |
| Dr. Scott M. Freeman M.D. | Co-Founder & Clinical Advisor | 314.81k | -- | 1957 |
| Mr. Leonard Latchman | Co-founder | -- | -- | -- |
| Ms. Carrie F. Liao C.P.A., CGMA | VP & Chief Accounting Officer | -- | -- | 1966 |
| Mr. Mark R. Sullivan J.D. | Chief Legal Officer & Corporate Secretary | -- | -- | 1971 |
| Dr. Francois P. Lilienthal M.B.A., M.D. | Chief Commercial Officer | -- | -- | -- |
Mind Medicine (MindMed) Inc.
One World Trade Center
Suite 8500
New York, NY 10007
United States
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 57
Description
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.
Corporate Governance
Mind Medicine (MindMed) Inc.’s ISS Governance QualityScore as of April 1, 2024 is 6. The pillar scores are Audit: 7; Board: 5; Shareholder Rights: 3; Compensation: 8.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Recent Events
- Apr 01, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Mar 18, 2024D: Additional FormsSee Full Filing
- Mar 11, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Mar 07, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Feb 28, 202410-K: Periodic Financial ReportsSee Full Filing
Upcoming Events
May 02, 2024 - May 06, 2024
Mind Medicine (MindMed) Inc. Earnings Call
Related Tickers
ATAI Atai Life Sciences N.V.
1.9300
+4.89%
CYBN Cybin Inc.
0.3500
+1.16%
CYBN.NE Cybin Inc.
0.4750
+3.26%
RXRX Recursion Pharmaceuticals, Inc.
8.12
+3.57%
OCGN Ocugen, Inc.
1.2800
+8.47%
IBRX ImmunityBio, Inc.
7.35
+43.84%
VKTX Viking Therapeutics, Inc.
74.31
+7.91%
CADL Candel Therapeutics, Inc.
6.39
-0.62%
CRSP CRISPR Therapeutics AG
53.91
+0.34%
CDTX Cidara Therapeutics, Inc.
12.63
-2.85%